New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
04:55 EDTTLOG, TLOG, TLOG, TLOG, TLOG, AG, AG, AG, AG, AG, FMI, FMI, FMI, FMI, FMI, NLNK, NLNK, NLNK, NLNK, NLNK, TSRO, TSRO, TSRO, TSRO, TSRO, FPRX, FPRX, FPRX, FPRX, FPRX, SNSS, SNSS, SNSS, SNSS, SNSS, TROV, TROV, TROV, TROV, TROV, AZN, AZN, AZN, AZN, AZN, MRK, MRK, MRK, MRK, MRK, PFE, PFE, PFE, PFE, PFE, NVS, NVS, NVS, NVS, NVS, PPHM, PPHM, PPHM, PPHM, PPHMAmerican Association of Cancer Research to hold annual meeting
2014 Annual Meeting 2014 is being held in San Diego, California on April 5-9.
News For TLOG;NVS;PFE;MRK;AZN;TROV;SNSS;FPRX;TSRO;NLNK;FMI;AG;PPHM From The Last 14 Days
Check below for free stories on TLOG;NVS;PFE;MRK;AZN;TROV;SNSS;FPRX;TSRO;NLNK;FMI;AG;PPHM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 16, 2014
09:27 EDTPFEPfizer to acquire InnoPharma for upfront cash payment of $225M
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTPFE, AZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:04 EDTPFEPfizer says primary endpoint met in Phase 3 study of BeneFIX
Pfizer announced the positive results of a Phase 3 study comparing a prophylaxis regimen of BeneFIX Coagulation Factor IX 100 IU/kg once-weekly to on-demand treatment in people with moderately severe to severe hemophilia B. The top-line results of the study showed that the primary study endpoint was met and hemophilia B patients taking once-weekly BeneFIX showed a statistically significant reduction in the annualized bleeding rate relative to on-demand treatment with BeneFIX. In the study, the median ABR value, a commonly used measure of efficacy for prophylaxis regimens in hemophilia, was 2.0 for the prophylaxis regimen, compared to 33.6 for the on-demand regimen, representing a 94% decrease in bleeding rates. The mean ABR value was 3.6 for the prophylaxis period, compared to 32.9 for the on-demand treatment, which represents a reduction of 89%. Study results also showed that prophylaxis treatment significantly reduced both spontaneous and traumatic ABR compared to on-demand treatment with BeneFIX. In addition to meeting the primary endpoint, the secondary study endpoints showed that none of the 1,254 prophylaxis infusions administered during the study were associated with a less than expected therapeutic effect occurrence, which was defined as a spontaneous bleed occurring within 48 hours of a prophylaxis infusion. These results are preliminary, top-line data and are subject to additional analyses. Complete results from this study will be submitted for presentation at upcoming medical congresses and submitted for publication in a peer-reviewed journal.
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
July 15, 2014
11:13 EDTMRKPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
08:11 EDTMRKMerck looks to revive livestock drug Zilmax, WSJ says
Merck has been preparing to conduct a large-scale study this summer to evaluate the safety of its Zilmax feed additive, which the company pulled from the U.S. market last year over concerns in the beef industry that the drug made it difficult for some animals to walk, reported The Wall Street Journal. Reference Link
07:35 EDTMRKPerrigo potential buyers list could be limited, says Jefferies
After Globes reported that Perrigo retained an investment bank to assist with a potential merger, Jefferies says the list of potential buyers could be limited since the store brand business is fundamentally a high volume, lower margin model. The firm notes U.S. companies that currently do not have large over-the-counter divisions include Bristol-Myers (BMY), Eli Lilly (LLY) and Merck (MRK). Jefferies views the merger speculation surrounding Perrigo as not surprising given the company's strong long-term fundamentals and attractive Irish domicile. It has a Buy rating on the stock with a $160 price target.
05:44 EDTNVSNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
05:35 EDTNVSNovartis collaborates with Banner Alzheimer's Institute on study
Novartis announced a collaboration with Banner Alzheimer's Institute, or BAI, on a pioneering clinical study in Alzheimer's disease, or AD, prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease. Using an innovative trial design, the two treatments will be given in cognitively healthy people at genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to AD. One treatment is an active immunotherapy, a treatment that stimulates an immune response, and triggers the production of natural antibodies against amyloid. This investigational treatment, given via an injection, is in phase II clinical development. The second treatment, a BACE inhibitor, is an oral medication about to enter phase I trials and is designed to prevent the production of different forms of amyloid.
July 14, 2014
18:15 EDTPPHMOn The Fly: After Hours Movers
Subscribe for More Information
16:04 EDTPPHMPeregrine reports Q4 EPS (6c), consensus (7c)
Reports Q4 revenue $6.47M, consensus $4.75M.
15:17 EDTPPHMNotable companies reporting after market close
Subscribe for More Information
07:23 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
07:04 EDTAGFirst Majestic announces spin-out of non-core exploration properties
Subscribe for More Information
07:02 EDTAGFirst Majestic announces 3.86M silver eqv. ounces produced in Q2
First Majestic announced that total production at its five operating silver mines in Mexico for the second quarter reached a new quarterly record of 3,855,224 equivalent ounces of silver, representing an 18% increase compared to the same quarter in 2013. Total silver production for the quarter consisted of 3,098,218 ounces of silver, representing an increase of 12% compared to the same quarter in 2013. In addition, 9,131,149 pounds of lead and 2,637,967 pounds of zinc were produced, representing an increase of 54% and a decrease of 9%, respectively, compared to the same quarter of the previous year. Also produced were 2,801 ounces of gold, representing an increase of 40% compared to the second quarter of 2013. The total ore processed during the quarter at the Company's five operating silver mines: La Encantada, La Parrilla, Del Toro, San Martin and La Guitarra, amounted to 671,024 tonnes, reflecting no significant variation year-over-year and represents a 5% increase over the previous quarter.
July 10, 2014
16:12 EDTMRKMedivation names Dawn Svoronos as Chief Commercial Officer
Medivation (MDVN) announced Dawn Svoronos has been appointed as its chief commercial officer, reporting to David Hung, M.D., founder, CEO and president of Medivation. Svoronos currently is a member of Medivation's Board of Directors and is a former president of Europe and Canada for Merck & Co. (MRK), where she oversaw commercial operations in approximately 30 EU and EU accession countries. Svoronos will lead Medivation's commercial organization on an interim basis and will participate in the company's search for a permanent chief commercial officer. Cheryl Cohen, Medivation's former chief commercial officer, has left the company to pursue other opportunities.
15:43 EDTNVSNovartis siponimod designated as orphan treatment of dermatomyositis
Subscribe for More Information
11:00 EDTAGHigh option volume stocks
High option volume stocks: CBS MEMP EWT CBSO DRWI TRW TTS EXK MEOH AG
10:05 EDTTROVOn The Fly: Analyst Initiation Summary
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use